Phone-based nurse support for breast cancer medication side effects
Part of Cancer, Skin clinical trials.
This study tests whether regular phone check-ins with a nurse can help catch and manage side effects from CDK4/6 inhibitor medications (like palbociclib, ribociclib, or abemaciclib) that you're taking for breast cancer. The goal is to help you stay on treatment safely and feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older
- You have been diagnosed with breast cancer (confirmed by biopsy)
- You are currently taking a CDK4/6 inhibitor medication for your breast cancer
- You have access to a phone or device to communicate with the study nurse
- You are able and willing to take part in regular check-in calls
- You do not have serious cognitive or psychiatric conditions that would make participation difficult
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with a common type of breast cancer that is hormone-receptor-positive and HER2-negative, and has a high risk of coming back. It looks at how well patients take a type of targeted therapy (CDK4/6 inhibitors) combined with hormone therapy after surgery, to help prevent recurrence.
This trial tests whether regular phone calls from a nurse can help patients after they finish their main cancer treatment. It focuses on breast, colorectal, or prostate cancer that was treated with a goal to cure.
This phase 2 trial compares ribociclib, palbociclib, and abemaciclib to see how each one affects your body’s immune response in estrogen- and/or progesterone-receptor–positive, HER2-negative early breast cancer. If you fit the stage and health requirements, joining could help doctors learn which treatment best “modulates” the immune system.
This trial looks at what happens when women with advanced hormone-positive, HER2-negative breast cancer stop taking a CDK4/6 inhibitor after at least a year of successful treatment. The goal is to see if it's safe to take a break from the CDK4/6 inhibitor while continuing hormone therapy alone.
This study looks at how well CDK4/6 inhibitors (a type of targeted therapy) work in real-world patients with HR+/HER2- advanced breast cancer. By collecting medical data from people treated at this hospital, doctors hope to learn more about the effectiveness and safety of these drugs in everyday practice.
This study tests a program to help people with metastatic breast cancer take their endocrine therapy, CDK4/6 inhibitors, and heart-related medications as prescribed. If you sometimes miss doses of these medicines, you may be able to join.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.